Tripura: BJP emerges as major challenge to CPI-M as Cong leaders turn saffron

Agencies
February 4, 2018

Agartala, Feb 4: The coming Assembly election in Tripura is likely to witness a fight between the CPI(M)-led Left Front and the BJP in the state.

The state had in the past witnessed an electoral battle between the CPI(M) and the Congress.

Sudip Roy Burman, former state Congress president and an MLA who had joined the BJP, said, "The Congress was not serious about fighting the CPI(M)" and claimed that the BJP would defeat the Marxists in the Assembly poll.

Burman, who headed the state Congress in 2013 Assembly election, told PTI, "In 2013, the CPI(M) had faced strong anti-incumbency but Congress central leadership had helped CPI(M) in the state clandestinely for enjoying the party's support in Parliament".

CPI(M) politburo member Prakash Karat also admitted that this time it is a contest between the Left Front and the BJP in the February 18 election.

"All the earlier elections in the state were fought between the Left Front and the Congress but this time, it is a contest between the BJP and the Left Front as Congress leaders and supporters had joined the saffron party", Karat had stated at an election meeting in South Tripura on Friday.

Six Congress MLAs including Burman had crossed over to the BJP.

"We are forced to join the BJP as we found that the Congress is not serious about fighting the CPI(M)", Burman said.

Tripura Congress vice-president, Tapas Dey said, "A communal party like the BJP became so strong in the state due to the misrule and partisan behaviour of the CPI(M)".

The CPI(M) never fulfilled the justified demands of the people, he said and alleged, "They (CPIM) have a vindictive attitude towards people who do not support them."

CPI(M) spokesperson Gautam Das said, Tripura is a model state in the country in terms of development.

"The pro-people programmes of the Left Front government, especially for the poor and the working class, would bring it back to power", he said.

To garner the tribal vote which constituted around 31 per cent in the state, BJP has stitched an alliance with the Indigenous People's Front of Tripura (IPFT).

"The alliance between BJP and IPFT will make a strong impact in the 20 tribal reserve constituencies," said Mrinal Kanti Deb, BJP spokesperson.

Karat had, however, alleged that the IPFT is the mask of insurgents, who had killed people of the state a decade-and- a-half ago.

The BJP forging an alliance with such a party was tantamount to "sedition", the senior CPI(M) leader had said.

That the BJP is very serious in wresting power from the CPI(M) is evident from the list of its star campaigners like Prime Minister Narendra Modi, Home minister Rajnath Singh, BJP president Amit Shah and a galaxy of party leaders who will campaign for party candidates in Tripura.

Cautioning the people in the state, Karat had said, "The Assembly election in the state is important not only for Tripura, but for entire India, as it would show which way the country would move".

Comments

shaji
 - 
Sunday, 4 Feb 2018

Dear Burmon, we want to know for which cost you have sold yourself in the hands of anti nationals and communal party.   Shame on.   People like you are sick and look for money + position.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 19,2020

Shimla, Apr 19: A man, who had recovered from the novel coronavirus, was again found suffering from the infection in Himachal Pradesh, officials said.

The man, a Tablighi Jamaat member, tested positive for the infection on Saturday within a week of his two reports coming out negative, they said.

Residents of different places in Mandi district, the man along with two other Jamaatis had been staying in a mosque of Nakroh village in Una'a Amb tehsil and all tested positive on April 2.

They were admitted to Tanda's Dr. Rajendra Prasad Government Medical College (RPGMC) in Kangra district on April 3.

As per the available information, they had tested negative for the first time on April 10 and they were declared as cured as per protocol after they tested negative for the second time on April 12.

Subsequently they had been discharged from the RPGMC and were kept in institutional quarantine.

However, with the man again testing positive, the total number of active cases in the hill state has increased to 23 out of the total 40 positive cases.

Four persons have been shifted to a private hospital outside the state. Eleven have recovered while two others have died.

A total of 16 confirmed cases were found in Una and health department statistics now shows 14 active cases and two cured.

Officials said 11 patients — three each from Chamba, Kangra, and Solan districts and two from Una district — have recovered.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 19,2020

New Delhi, Jun 19: Delhi minister Satyendar Jain's health has deteriorated further. He is infected with the coronavirus. Jain has also been diagnosed with pneumonia. He is being shifted to an ICU.  According to doctors, Jain is now kept full-time on oxygen support as his oxygen saturation level has dipped.  

Jain was admitted to Rajiv Gandhi Super Speciality Hospital early Tuesday after running high fever and suffering a sudden drop in oxygen level. The 55-year-old leader's test result came positive on Wednesday evening after a second test. Jain was brought to the hospital and was administered a test for the novel coronavirus infection on Tuesday morning, for which he tested negative. But he still ran fever and showed symptoms, so another test was done after 24 hours of the first.

He will now be shifted Max Hospital in Saket and administered plasma therapy. 

Union Home Minister Amit Shah has also wished for Jain's speedy recovery.

On Thursday, Delhi Deputy Chief Minister Manish Sisodia took over the charge of health, PWD, power and other departments held by Jain. Jain will remain the cabinet minister without any portfolio in the Arvind Kejriwal government until he recovers. 

On Sunday, Jain attended a high-level meeting on the coronavirus situation in the national capital, chaired by Union Home Minister Amit Shah, which was also attended by Delhi Lt Governor Anil Baijal, Kejriwal, Sisodia and Union Health Minister Harsh Vardhan.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.